Search BIXT
BIOXYTRAN, INC
OTC · CIK 1445815
Last close0.02
Daily change-0.00 (-0.00%)
10 Years gain-98.48%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BIXT · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
7.2Momentum
n/aAcceleration
n/aConfidence
69.0Annual Revenue8
Quarterly Revenue29
Annual CFO16
Balance SheetMissing
RankingLimited
Score Breakdown
Growth0.0 / 25
Quality6.8 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Key Metrics
Revenue Growth TTM-5.44%OK
Revenue CAGR 3Y-11.5%OK
Gross Margin59.67%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $0.00 | -$1.84M | -$526,455.00 | n/a | n/a | n/a | n/a | n/a | 91.84M |
| 2025 FY Dec 31, 2024 | n/a | $0.00 | -$2.22M | -$381,316.00 | n/a | n/a | n/a | n/a | n/a | 138.6M |
| 2024 FY Dec 31, 2023 | n/a | $0.00 | -$3.80M | -$775,375.00 | n/a | n/a | n/a | n/a | n/a | 133.97M |
| 2023 FY Dec 31, 2022 | n/a | $0.00 | -$2.44M | -$1.80M | n/a | n/a | n/a | n/a | n/a | 112.71M |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$4.21M | -$1.70M | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $185,077.00 | sum latest 4 fiscal quarters Revenue | OK | 0001213900-18-009902, 0001213900-17-011486 |
| Revenue Growth TTM | -5.44% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001213900-18-009902, 0001213900-17-011486 |
| Revenue CAGR 3Y | -11.5% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001213900-18-003761 |
| Revenue CAGR 5Y | -9.39% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001213900-18-003761 |
| Gross Profit CAGR 3Y | -7.39% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001213900-18-003761 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 59.67% | Gross Profit / Revenue | OK | 0001213900-18-009902, 0001213900-17-011486 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001213900-18-009902 |
| Cash / Debt | 0x | (Cash + Short-term Investments) / Total Debt | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001213900-18-003761 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | 0001213900-18-009902, 0001213900-17-011486 |